Developer docs
API playgroundTry for free, no card

Search company profiles

Q-Sera

Full company profile

uuid000gzb5

Namestring
Q-Sera
Legal namestring
Q-Sera Pty Ltd
Websiteurl
q-sera.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Q-Sera Pty Ltd is an Australian venture-backed biotechnology company founded in 2012 and headquartered in Melbourne that develops proprietary blood collection tubes based on RAPClot, a recombinantly manufactured prothrombin activator (recombinant ecarin) originally derived from Australian Taipan snake venom. The company's core technology combines RAPClot with a patented protective formulation to produce serum in under five minutes, including from anticoagulated blood samples (effective against heparin up to 6U/ml, warfarin, and direct oral anticoagulants), addressing a long-standing inefficiency in standard silica-based clot activator tubes that take 15-30 minutes and often fail on anticoagulated patients. The technology is patent-protected through 2035 across 13 major jurisdictions.

Q-Sera's commercial model is asset-light licensing: it supplies RAPClot recombinant ecarin manufactured at commercial scale under GMP by partner Bora Biologics (formerly JHL Biotech) to medical device licensees who incorporate it into their own blood collection tube brands. Terumo Corporation is the anchor licensee, holding exclusive Japan rights and launching the product as VenoJect II RAPClot in January 2026. Q-Sera is actively soliciting additional licensing partners for blood collection tube and diagnostic markets outside Japan. Revenue streams consist of licensing/royalty income and recombinant ecarin supply to partners, with no direct-to-end-user sales.

The company's customer base is currently a single enterprise licensee (Terumo) with hospital and pathology laboratory end-users reached indirectly through partner distribution. Scientific leadership draws on University of Queensland researchers whose PhD work underpinned the primary patent, supplemented by a CEO with CSL coagulation commercial development experience. Key capital providers include Brandon BioCatalyst/MRCF, Uniseed, CSIRO, and Australian Government commercialization programs.

Short descriptiontext

Q-Sera is an Australian biotech that licenses RAPClot recombinant ecarin technology to medical device manufacturers for use in rapid-serum blood collection tubes, with Terumo Corporation as its anchor licensee in Japan and active partner outreach for other geographies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood collection tubes, recombinant ecarin, serum production, prothrombin activators, in vitro diagnostics
Industry1 code
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics — Blood Collection Tubes
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

Q-Sera generates revenue through exclusive licensing agreements with medical device companies. Terumo Corporation holds exclusive rights to manufacture and market VenoJect II RAPClot tubes in Japan. The company is pursuing similar licensing arrangements for other geographic markets and diagnostic sectors.

q-sera.com
2Recombinant Ecarin Supply
TypeHardware Sales
Description

Supply of RAPClot recombinant ecarin to license partners for use in blood collection tubes and diagnostic/medical device applications. Manufacturing is done through Bora Biologics using GMP processes.

q-sera.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1RAPClot
Description

RAPClot is the company's recombinant ecarin technology used in blood collection tubes for rapid serum production. It is manufactured recombinantly using standard biopharmaceutical processes.

q-sera.com
+1 more record
Core offering1 text field

Q-Sera develops and manufactures RAPClot recombinant ecarin, a prothrombin activator protein originally derived from Australian Taipan snake venom and produced recombinantly via GMP biopharmaceutical processes. The protein is supplied to medical device license partners and formulated into RAPClot Rapid Serum blood collection tubes that clot most samples in under 5 minutes and effectively clot anticoagulated blood (heparin up to 6U/ml, warfarin, DOACs). Q-Sera operates a B2B licensing model, with Terumo Corporation holding exclusive Japan rights and launching VenoJect II RAPClot tubes in January 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Clotting time reduced to under 5 minutes for majority of samples
+4 more records
Product overview1 text field

Q-Sera is a biotech company commercializing RAPClot technology, a novel blood collection tube system. The core product is RAPClot Rapid Serum Tubes containing recombinant ecarin (RAPClot), a prothrombin activator originally derived from snake venom (Australian Taipan). These tubes represent a new standard biochemistry tube that rapidly produces high-quality serum in under 5 minutes, even from anticoagulated blood samples. The technology is protected by global patents through 2035. Q-Sera manufactures RAPClot recombinant ecarin at commercial scale through its manufacturing partner Bora Biologics. The product is distributed in Japan through Terumo Corporation's Venoject II RAPClot brand.

Product and service3 records
1RAPClot Rapid Serum Tubes
CategoryBlood collection tubes / In vitro diagnostics
Description

Proprietary blood collection tubes containing recombinant ecarin (RAPClot) and a patented protective formulation that rapidly produce high-quality serum in under 5 minutes. The tubes efficiently clot blood samples, including samples from anticoagulated patients on warfarin, heparin (up to 6U/ml), and direct oral anticoagulants. Formulated for room temperature stability and compatibility with Gamma and E-Beam sterilization. Sold to healthcare facilities through licensed medical device manufacturers.

2RAPClot Recombinant Ecarin
CategoryBioproduct / Recombinant protein reagent
Description

High-purity recombinant ecarin protein manufactured using standard biopharmaceutical production and purification processes from a GMP master Cell Bank. High yielding and low cost; supply is unlimited and can be manufactured at any required quality level. Supplied to license partners for incorporation into blood collection tubes and other diagnostic/medical device applications.

3VenoJect II RAPClot
CategoryBlood collection tubes (licensed sub-brand)
Description

Terumo Corporation's branded version of RAPClot rapid serum tubes marketed in Japan as part of the Venoject II tube range. Evacuated blood collection tubes incorporating Q-Sera's patent-protected RAPClot recombinant ecarin, formulated to clot up to 6U/ml heparin. Represents the first real innovation in the Japanese blood collection tube market in decades.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Terumo Corporation
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-11-01
Description

Terumo Corporation holds exclusive rights to use Q-Sera's technology to manufacture and market VenoJect II RAPClot evacuated blood collection tubes in Japan. In January 2026, Terumo successfully launched these next-generation tubes in the Japanese market. Terumo is a global medical innovation company founded in Tokyo in 1921, providing solutions in therapeutic procedures, hospital operations, and life sciences in over 160 countries.

q-sera.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Bora Biologics (formerly JHL Biotech) collaborated with Q-Sera to produce high-yielding recombinant ecarin for commercial scale production of RAPClot Rapid Serum tubes. Bora Biologics has successfully scaled-up RAPClot manufacturing to commercial scale using standard biopharmaceutical processes with a GMP master cell bank. This enables RAPClot to be manufactured at any quality level required for diagnostic and medical device use.

Strategic tierCoreTypeTechnology or Integration
Description

Q-Sera's technology is based on intellectual property from The University of Queensland (UQ) Centre for Clinical Research. UniQuest, UQ's commercialization company, identified and developed the technology and licensed it to Q-Sera. The technology involves using prothrombin activators originally identified from snake venom to accelerate blood clotting in improved blood collection tubes.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Q-Sera

In Vitro Diagnostics — Blood Collection Tubesq-sera.com

Q-Sera is an Australian biotech that licenses RAPClot recombinant ecarin technology to medical device manufacturers for use in rapid-serum blood collection tubes, with Terumo Corporation as its anchor licensee in Japan and active partner outreach for other geographies.

What Q-Sera does

Q-Sera Pty Ltd is an Australian venture-backed biotechnology company founded in 2012 and headquartered in Melbourne that develops proprietary blood collection tubes based on RAPClot, a recombinantly manufactured prothrombin activator (recombinant ecarin) originally derived from Australian Taipan snake venom. The company's core technology combines RAPClot with a patented protective formulation to produce serum in under five minutes, including from anticoagulated blood samples (effective against heparin up to 6U/ml, warfarin, and direct oral anticoagulants), addressing a long-standing inefficiency in standard silica-based clot activator tubes that take 15-30 minutes and often fail on anticoagulated patients. The technology is patent-protected through 2035 across 13 major jurisdictions.

Q-Sera's commercial model is asset-light licensing: it supplies RAPClot recombinant ecarin manufactured at commercial scale under GMP by partner Bora Biologics (formerly JHL Biotech) to medical device licensees who incorporate it into their own blood collection tube brands. Terumo Corporation is the anchor licensee, holding exclusive Japan rights and launching the product as VenoJect II RAPClot in January 2026. Q-Sera is actively soliciting additional licensing partners for blood collection tube and diagnostic markets outside Japan. Revenue streams consist of licensing/royalty income and recombinant ecarin supply to partners, with no direct-to-end-user sales.

The company's customer base is currently a single enterprise licensee (Terumo) with hospital and pathology laboratory end-users reached indirectly through partner distribution. Scientific leadership draws on University of Queensland researchers whose PhD work underpinned the primary patent, supplemented by a CEO with CSL coagulation commercial development experience. Key capital providers include Brandon BioCatalyst/MRCF, Uniseed, CSIRO, and Australian Government commercialization programs.

Q-Sera firmographics

Firmographics
Name
Q-Sera
Legal name
Q-Sera Pty Ltd
Website
https://q-sera.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Q-Sera is an Australian biotech that licenses RAPClot recombinant ecarin technology to medical device manufacturers for use in rapid-serum blood collection tubes, with Terumo Corporation as its anchor licensee in Japan and active partner outreach for other geographies.
Ownership category
akta.pro rank

Q-Sera industry classification

Industry
Product category
In Vitro Diagnostics — Blood Collection Tubes
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Blood collection tubes
  • Recombinant ecarin
  • Serum production
  • Prothrombin activators
  • In vitro diagnostics

Where Q-Sera is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Q-Sera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing Revenue: Q-Sera generates revenue through exclusive licensing agreements with medical device companies. Terumo Corporation holds exclusive rights to manufacture and market VenoJect II RAPClot tubes in Japan. The company is pursuing similar licensing arrangements for other geographic markets and diagnostic sectors.
  2. Recombinant Ecarin Supply: Supply of RAPClot recombinant ecarin to license partners for use in blood collection tubes and diagnostic/medical device applications. Manufacturing is done through Bora Biologics using GMP processes.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Q-Sera product offering

Product offering

Core offering

Q-Sera develops and manufactures RAPClot recombinant ecarin, a prothrombin activator protein originally derived from Australian Taipan snake venom and produced recombinantly via GMP biopharmaceutical processes. The protein is supplied to medical device license partners and formulated into RAPClot Rapid Serum blood collection tubes that clot most samples in under 5 minutes and effectively clot anticoagulated blood (heparin up to 6U/ml, warfarin, DOACs). Q-Sera operates a B2B licensing model, with Terumo Corporation holding exclusive Japan rights and launching VenoJect II RAPClot tubes in January 2026.

Product overview

Q-Sera is a biotech company commercializing RAPClot technology, a novel blood collection tube system. The core product is RAPClot Rapid Serum Tubes containing recombinant ecarin (RAPClot), a prothrombin activator originally derived from snake venom (Australian Taipan). These tubes represent a new standard biochemistry tube that rapidly produces high-quality serum in under 5 minutes, even from anticoagulated blood samples. The technology is protected by global patents through 2035. Q-Sera manufactures RAPClot recombinant ecarin at commercial scale through its manufacturing partner Bora Biologics. The product is distributed in Japan through Terumo Corporation's Venoject II RAPClot brand.

Differentiator

Problem solved

Functional benefit

Brands

  • RAPClot: RAPClot is the company's recombinant ecarin technology used in blood collection tubes for rapid serum production. It is manufactured recombinantly using standard biopharmaceutical processes.
  • VenoJect II RAPClot

Products and services

  • RAPClot Rapid Serum Tubes Proprietary blood collection tubes containing recombinant ecarin (RAPClot) and a patented protective formulation that rapidly produce high-quality serum in under 5 minutes. The tubes efficiently clot blood samples, including samples from anticoagulated patients on warfarin, heparin (up to 6U/ml), and direct oral anticoagulants. Formulated for room temperature stability and compatibility with Gamma and E-Beam sterilization. Sold to healthcare facilities through licensed medical device manufacturers.
  • RAPClot Recombinant Ecarin High-purity recombinant ecarin protein manufactured using standard biopharmaceutical production and purification processes from a GMP master Cell Bank. High yielding and low cost; supply is unlimited and can be manufactured at any required quality level. Supplied to license partners for incorporation into blood collection tubes and other diagnostic/medical device applications.
  • VenoJect II RAPClot Terumo Corporation's branded version of RAPClot rapid serum tubes marketed in Japan as part of the Venoject II tube range. Evacuated blood collection tubes incorporating Q-Sera's patent-protected RAPClot recombinant ecarin, formulated to clot up to 6U/ml heparin. Represents the first real innovation in the Japanese blood collection tube market in decades.

Quantifiable outcome

  • Clotting time reduced to under 5 minutes for majority of samples
  • +4 more outcomes

Companies that use Q-Sera

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Q-Sera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Q-Sera partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Terumo CorporationcoreOEM/ Whitelabel/ Licensing Partner · 1 November 2021Terumo Corporation holds exclusive rights to use Q-Sera's technology to manufacture and market VenoJect II RAPClot evacuated blood collection tubes in Japan. In January 2026, Terumo successfully launched these next-generation tubes in the Japanese market. Terumo is a global medical innovation company founded in Tokyo in 1921, providing solutions in therapeutic procedures, hospital operations, and life sciences in over 160 countries.
  • Bora Biologics Co., LtdcoreStrategic or Co-development Partner · 1 May 2020Bora Biologics (formerly JHL Biotech) collaborated with Q-Sera to produce high-yielding recombinant ecarin for commercial scale production of RAPClot Rapid Serum tubes. Bora Biologics has successfully scaled-up RAPClot manufacturing to commercial scale using standard biopharmaceutical processes with a GMP master cell bank. This enables RAPClot to be manufactured at any quality level required for diagnostic and medical device use.
  • University of Queensland / UniQuestcoreTechnology or IntegrationQ-Sera's technology is based on intellectual property from The University of Queensland (UQ) Centre for Clinical Research. UniQuest, UQ's commercialization company, identified and developed the technology and licensed it to Q-Sera. The technology involves using prothrombin activators originally identified from snake venom to accelerate blood clotting in improved blood collection tubes.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Q-Sera competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Q-Sera social profiles

Digital presence

Q-Sera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Q-Sera leadership team

Management profile

Number of profiles

Profiles6 records

Q-Sera funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Q-Sera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q-Sera

What does Q-Sera do?

Q-Sera develops and manufactures RAPClot recombinant ecarin, a prothrombin activator protein originally derived from Australian Taipan snake venom and produced recombinantly via GMP biopharmaceutical processes. The protein is supplied to medical device license partners and formulated into RAPClot Rapid Serum blood collection tubes that clot most samples in under 5 minutes and effectively clot anticoagulated blood (heparin up to 6U/ml, warfarin, DOACs). Q-Sera operates a B2B licensing model, with Terumo Corporation holding exclusive Japan rights and launching VenoJect II RAPClot tubes in January 2026.

Is Q-Sera a public or private company?

Q-Sera is a private company. It is classified as venture growth investor backed and is currently operating.

When was Q-Sera founded?

Q-Sera was founded in 2012. It employs 1 to 10 people.

Where is Q-Sera based?

Q-Sera is headquartered in Melbourne, Australia, in the Oceania region.

How does Q-Sera make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are recombinant Ecarin Supply.

Does Q-Sera have an API?

No public API is recorded for Q-Sera.

What industry is Q-Sera in?

Q-Sera's product category is In Vitro Diagnostics — Blood Collection Tubes. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales